INVA - Innoviva Inc
Innoviva Inc Logo

INVA - Innoviva Inc

https://www.inva.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Almonty Indus ( NASDAQ:ALM ) , ARM Holdings ( NASDAQ:ARM )
Benzinga • 1 month ago • score: 0.35
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Crescent Biopharma, Inc.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.

52W High
$22.00
52W Low
$16.67
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.47
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
35.93
Forward P/E (<15 better)
8.42
EV/EBITDA (<8 favorable)
11.15
EV/Revenue (<3 favorable)
3.36
P/S (TTM) (<3 favorable)
3.49
P/B (<3 favorable)
1.81
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.98%
Institutions (25–75% balanced)
122.08%
Shares Outstanding
63,021,000
Float
57,648,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
2015-09-08
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
370,229,000
Gross Profit (TTM)
318,186,000
EPS (TTM)
0.57
Profit Margin (>10% good)
0.10%
Operating Margin (TTM) (higher better)
0.49%
ROE (TTM) (>15% strong)
0.06%
EPS YoY (Quarterly) (>10% good)
-0.63
Revenue YoY (Quarterly) (>8% good)
0.00
Momentum
Bearish momentum
Value
0.3830
Previous
0.4092
Trend
Falling
Signal Cross
No cross
As of
Sep. 05, 2025